Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Intravenous Doses of BI 655130 (Double-blind, Partially Randomised Within Dose Groups, Placebo-controlled Parallel Group Design) and One Single Intravenous Dose of BI 655130 (Single-blind, Partially Randomised, Placebo-controlled) in Healthy Male Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 May 2017
At a glance
- Drugs BI 655130 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Feb 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
- 22 Feb 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Aug 2017.